Fig. 2: Molecular characterization of Pre-treatment GBM tumors. | Nature Communications

Fig. 2: Molecular characterization of Pre-treatment GBM tumors.

From: Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial

Fig. 2

A Oncoplot of recurrent somatic mutations. B Unsupervised clustering of tumors based on global gene mutation profiling. C Kaplan-Meier curve of OS for patients with EGFR vs. PTEN mutant GBM tumors. The Cox proportional hazards model-derived hazard ratio and p-value from the Wald test are displayed. Source data are provided as a Source Data file. D Unsupervised clustering of GBM tumors based on transcriptome analysis. E Kaplan-Meier curve of OS for patients with cluster 1 vs. cluster 2 GBM tumors. The Cox proportional hazards model-derived hazard ratio and p-value from the Wald test are displayed.

Back to article page